Example collocations logo

Vaccine in sentence

824 examples of Vaccine in a sentence

The infrastructure put in place to deliver polio vaccines there is now being used to increase coverage of routine immunization, like the 5-in-1 pentavalent vaccine.
In some cases, such as Northern Nigeria, social resistance to the vaccine has blocked adequate coverage of the population.
And, in rare cases, the vaccine itself has failed and led to infection.
The solution is therefore not much more complicated than a polio vaccine.
This has forced productive research laboratories to close, putting potentially life-saving research – like that on an Ebola vaccine – on the back burner.
In Nigeria, the organization Education as a Vaccine – a partner of the International Women’s Health Coalition – could face a similarly unmanageable situation if they accept US HIV funding.
Yet half of the world’s children live in areas where the pneumococcal vaccine is not available through a national immunization program, and only 15% of the children in the world’s poorest countries have access to the rotavirus vaccine.
The three largest global health-financing institutions (the Global Fund to Fight AIDS, Tuberculosis, and Malaria, the GAVI Alliance, and UNITAID) will have spent more than $55 billion by 2015, with roughly $7 billion coming from innovative financing mechanisms such as vaccine bonds, the airline levy, and debt swaps.
More recently, researchers discovered an Ebola vaccine that provides 100% protection against the virus.
Consider his foundation’s approach to malaria, which focuses on bed nets, a low-tech, only modestly effective intervention, and on the development of a vaccine, a high-tech solution that has eluded intensive efforts for decades.
But resistance has arisen and will surely increase, so that in the absence of a vaccine, elimination of the mosquitoes that spread the disease is the key to preventing epidemics.
Unlike HIV, there is a vaccine against TB (although not very effective), and several drugs that can reliably cure the disease after it emerges.
Rapid response is required of governments, United Nations agencies, regulatory authorities, and the pharmaceutical industry for coordination, surveillance, and vaccine production.
One of the most exciting – and often overlooked – developments in the global push to give all children access to immunization is the growing role of emerging-country vaccine suppliers.
Thanks to the efforts of these suppliers and their close partnerships with the GAVI Alliance, multinational vaccine manufacturers, and international donors, more than 100 million children a year – more than ever before – are being immunized.
Consider the progress that has been made with the lifesaving pentavalent vaccine, which protects a child against diphtheria, tetanus, whooping cough, hepatitis B, and haemophilus influenza type b (Hib) – all in one dose.
As demand for the vaccine grew, GAVI encouraged other suppliers to enter the market, and the price tumbled.
Now there are five suppliers, and Biological E, an Indian pharmaceutical company, announced earlier this year that it would offer the vaccine for just $1.19 per dose.
India’s Department of Biotechnology and Bharat Biotech announced plans this year to release a new vaccine against rotavirus – which kills hundreds of thousands of children – for $1 per dose, significantly cheaper than existing vaccines.
Likewise, a Chinese biotech company won approval in October from the World Health Organization to bring to market an improved vaccine protecting children against Japanese encephalitis.
The same month, Brazil’s top biomedical research and development center, Bio-Manguinhos, in partnership with the Gates Foundation, announced plans to produce a combined measles and rubella vaccine.
The vaccine field was dominated by a handful of multinational pharmaceutical companies in rich countries, and the entire sector suffered from a lack of competition.
The contributions of emerging-country vaccine producers often complement the work of their counterparts in developed countries.
The Gates Foundation supported a major partnership between the Serum Institute of India and SynCo Bio Partners, a Dutch vaccine producer, to produce a low-cost vaccine to protect more than 450 million people in Africa from meningitis.
This year, Biological E announced two major partnerships with multinational vaccine manufacturers.
A joint partnership with GlaxoSmithKline will produce a six-in-one vaccine protecting children against polio and other infectious diseases; another, with Novartis, will produce two vaccines that will protect millions of people in the developing world from typhoid and paratyphoid fevers.
Emerging-country vaccine suppliers are a critical part of this process.
Vaccine coverage in the world’s richest countries varies, but in some places it is less than 30%.
Alarmingly, in some of the wealthy countries, where both screening and treatment should be readily available, vaccine coverage now appears to be declining, raising a real danger that socioeconomically disadvantaged girls there will face a similar fate.
If it turns out that girls at risk of not receiving all three doses of the HPV vaccine are also those with an elevated risk of being infected and missing cervical screenings as adults, they may be slipping through not one but two nets.
BackNext